MedPath

Bellerophon Therapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$428.1K
Website

Clinical Trials

6

Active:0
Completed:2

Trial Phases

3 Phases

Early Phase 1:1
Phase 1:1
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (50.0%)
Early Phase 1
1 (25.0%)
Phase 1
1 (25.0%)

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Phase 2
Conditions
Pulmonary Hypertension
Pulmonary Fibrosis
First Posted Date
2023-02-28
Last Posted Date
2023-02-28
Lead Sponsor
Bellerophon
Target Recruit Count
85
Registration Number
NCT05747508
Locations
🇺🇸

Arizona Pulmonary Specialists, Phoenix, Arizona, United States

🇺🇸

University of California, Los Angeles, California, United States

🇺🇸

University of California Davis Health, Sacramento, California, United States

and more 20 locations

Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Conditions
Pulmonary Fibrosis
Pulmonary Hypertension
First Posted Date
2022-05-02
Last Posted Date
2023-02-21
Lead Sponsor
Bellerophon
Registration Number
NCT05356052

Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19

Conditions
Coronavirus Infection
COVID-19
Pneumonia, Viral
First Posted Date
2020-04-24
Last Posted Date
2023-02-21
Lead Sponsor
Bellerophon
Registration Number
NCT04358588

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

Phase 2
Completed
Conditions
Pulmonary Hypertension
Sarcoidosis, Pulmonary
Pulmonary Fibrosis
First Posted Date
2018-11-01
Last Posted Date
2022-08-10
Lead Sponsor
Bellerophon
Target Recruit Count
17
Registration Number
NCT03727451
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

🇺🇸

Temple University, Philadelphia, Pennsylvania, United States

and more 3 locations

Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen

Early Phase 1
Terminated
Conditions
COPD
Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension
Interventions
Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr
First Posted Date
2017-05-01
Last Posted Date
2023-02-21
Lead Sponsor
Bellerophon
Target Recruit Count
7
Registration Number
NCT03135860
Locations
🇧🇪

Antwerp University Hospital, Edegem, Belgium

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.